|Articles|June 1, 1998

June 1998
Volume 4
Issue 6

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Author(s)Michael T. Halpern, MD, PhD, Cynthia S. Palmer, MSc, C. Stephen Foster, MD

Download PDF: A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

over 27 years ago

Article

Correspondence regarding, "Screening and Surveillance for Colorectal Cancer"

over 27 years ago

Article

"Carving Out" Conditions From Global Capitation Rates: Protecting High-Cost Patients, Physicians, and Health Plans in a Managed Care Environment

over 27 years ago

Article

Delivery of Preventive Healthcare to Older African-American Patients: A Performance Comparison from Two Practice Models

over 27 years ago

Article

Insurance Type and the Transportation to Emergency Departments of Patients with Acute Cardiac Ischemia: The ACI-TIPI Trial Insurance Study

over 27 years ago

Article

Does Competition by Health Maintenance Organizations Affect the Adoption of Cost-Containment Measures by Fee-for-Service Plans?

over 27 years ago

Article

Safety and Clinical Efficacy of Zileuton in Patients with Chronic Asthma

over 27 years ago

Article

Identification and Case Management in an HMO of Patients at Risk of Preterm Labor

over 27 years ago

Article

A Closer Look at Lower Back Pain

over 27 years ago

Article

Food Borne Illnesses in the United States: Office Recognition and Management

over 27 years ago

Article

Rheumatoid Arthritis: Focus on Appropriate Drug Therapy

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

A Pharmacoeconomic Analysis of Rimelolone for the Treatment of Ophthalmic Inflammatory Conditions

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

AI-Supported Mammography Caught More Cancers During Screening

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment